Holen Sie sich die Stockscreener-App
19.53
3.15%
-0.78
Schlusskurs vom Vortag:
$20.31
Offen:
$19.38
24-Stunden-Volumen:
645.52K
Relative Volume:
0.27
Marktkapitalisierung:
$3.65B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-451.71M
KGV:
-6.0537
EPS:
-3.2261
Netto-Cashflow:
$-462.19M
1W Leistung:
-21.76%
1M Leistung:
-25.07%
6M Leistung:
+11.19%
1J Leistung:
+48.45%
1-Tages-Spanne:
$18.97
$19.98
1-Wochen-Bereich:
$17.00
$25.39
52-Wochen-Spanne:
$11.92
$27.30
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.53 | 3.79B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
520.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.47 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
998.39 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.04 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.72 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN) - Seeking Alpha
RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
Dyne Therapeutics (DYN) officer plans $106K stock sale - Stock Titan
Dyne Therapeutics (Nasdaq: DYN) officer to sell 3,000 shares from RSUs - Stock Titan
Dyne Therapeutics (DYN) CCO’s tax sales leave 102,966 unvested RSUs - Stock Titan
Tax-driven stock sale by Dyne (DYN) medical chief - Stock Titan
Dyne Therapeutics (DYN) CEO sells shares to cover taxes - Stock Titan
Raymond James sets Dyne Therapeutics price targ... - Pluang
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling - Benzinga
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Canada
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 at Upcoming Medical Meetings - Investing News Network
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - RTTNews
Dyne Therapeutics (DYN) Shares Plunge 28% After Novartis Phase I - GuruFocus
Dyne Therapeutics (DYN) Faces Market Pressure After Novartis DM1 - GuruFocus
Dyne Therapeutics (DYN) Faces Pressure After Novartis Trial Fail - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings - Yahoo Finance
Dyne Therapeutics stock faces pressure after rival drug fails trial - Investing.com
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed - Yahoo Finance
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com India
Why is Dyne Therapeutics stock plummeting today? - Investing.com
Why is Dyne Therapeutics stock plummeting today? By Investing.com - Investing.com Canada
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History - Yahoo Finance
Dyne Therapeutics (NASDAQ: DYN) officer plans $121,745 share sale - Stock Titan
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy at 27th Annual NMSG Scientific Meeting - Investing News Network
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting - The Manila Times
Dyne Therapeutics Announces Preclinical Data Supporting Four DMD Exon-Skipping Candidates Advancing Into IND-Enabling Studies - Quiver Quantitative
Four experimental treatments for Duchenne muscular dystrophy move toward human testing - Stock Titan
Dyne Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
How Dyne Therapeutics Inc. (DYN) Affects Rotational Strategy Timing - Stock Traders Daily
How FDA Greenlight For DYNE-302 And Equity Raise At Dyne Therapeutics (DYN) Has Changed Its Investment Story - Sahm
Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Q3 EPS Forecast for Dyne Therapeutics Decreased by Analyst - MarketBeat
Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock By Investing.com - Investing.com Nigeria
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $54,012,900.00 in Stock - MarketBeat
Dyne Therapeutics CCO Executes Automatic Sale of 226 Shares to Cover RSU Tax Withholding - Kalkine Media
Dyne Therapeutics CEO John Cox Sells 4,986 Shares to Cover Tax Withholding on RSUs - Kalkine Media
Dyne therapeutics director Jason Rhodes sells $65.2m of common stock - Investing.com
Dyne Therapeutics (DYN) director's preset stock sale via Atlas funds - Stock Titan
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock - Investing.com
Dyne Therapeutics (DYN) CFO sells shares in tax withholding trade - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CCO sells shares to cover taxes - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CMO has shares sold for tax withholding - Stock Titan
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):